Immutep (IMMP) Competitors $1.54 +0.09 (+6.21%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.48 -0.06 (-3.83%) As of 04/17/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. ETNB, COLL, DYN, ELVN, RCUS, CMRX, CDMO, SYRE, NTLA, and ZYMEShould you be buying Immutep stock or one of its competitors? The main competitors of Immutep include 89bio (ETNB), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Arcus Biosciences (RCUS), Chimerix (CMRX), Avid Bioservices (CDMO), Spyre Therapeutics (SYRE), Intellia Therapeutics (NTLA), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Immutep vs. 89bio Collegium Pharmaceutical Dyne Therapeutics Enliven Therapeutics Arcus Biosciences Chimerix Avid Bioservices Spyre Therapeutics Intellia Therapeutics Zymeworks Immutep (NASDAQ:IMMP) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Which has stronger valuation & earnings, IMMP or ETNB? Immutep has higher revenue and earnings than 89bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmutep$5.14M43.75-$28.01MN/AN/A89bioN/AN/A-$142.19M-$3.43-1.77 Does the media favor IMMP or ETNB? In the previous week, 89bio had 10 more articles in the media than Immutep. MarketBeat recorded 10 mentions for 89bio and 0 mentions for Immutep. 89bio's average media sentiment score of 0.36 beat Immutep's score of 0.00 indicating that 89bio is being referred to more favorably in the news media. Company Overall Sentiment Immutep Neutral 89bio Neutral Which has more volatility and risk, IMMP or ETNB? Immutep has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Is IMMP or ETNB more profitable? Immutep's return on equity of 0.00% beat 89bio's return on equity.Company Net Margins Return on Equity Return on Assets ImmutepN/A N/A N/A 89bio N/A -59.58%-52.21% Do institutionals & insiders have more ownership in IMMP or ETNB? 2.3% of Immutep shares are held by institutional investors. 3.1% of Immutep shares are held by company insiders. Comparatively, 2.8% of 89bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in IMMP or ETNB? Immutep received 198 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 72.56% of users gave Immutep an outperform vote while only 62.98% of users gave 89bio an outperform vote. CompanyUnderperformOutperformImmutepOutperform Votes31272.56% Underperform Votes11827.44% 89bioOutperform Votes11462.98% Underperform Votes6737.02% Do analysts recommend IMMP or ETNB? Immutep currently has a consensus target price of $8.50, indicating a potential upside of 451.95%. 89bio has a consensus target price of $27.56, indicating a potential upside of 354.71%. Given Immutep's stronger consensus rating and higher probable upside, analysts plainly believe Immutep is more favorable than 89bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.0089bio 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 SummaryImmutep beats 89bio on 11 of the 15 factors compared between the two stocks. Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricImmutepPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$211.76M$6.45B$5.30B$7.35BDividend YieldN/A3.25%5.12%4.31%P/E RatioN/A6.8821.7117.77Price / Sales43.75231.36379.3997.68Price / CashN/A65.6738.2234.64Price / Book1.475.916.443.98Net Income-$28.01M$142.72M$3.21B$247.44M7 Day Performance9.22%7.98%5.24%4.44%1 Month Performance-15.38%-13.91%-9.49%-7.73%1 Year Performance-31.86%-9.98%11.01%1.28% Immutep Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPImmutep1.0559 of 5 stars$1.54+6.2%$8.50+451.9%-31.9%$211.76M$5.14M0.002,021Gap DownETNB89bio2.5768 of 5 stars$5.92+7.1%$27.56+365.5%-33.8%$864.23MN/A-2.0340Short Interest ↑COLLCollegium Pharmaceutical4.1875 of 5 stars$26.73+1.6%$43.60+63.1%-23.8%$858.89M$631.45M11.52210Positive NewsDYNDyne Therapeutics3.5447 of 5 stars$7.47+6.1%$47.46+535.4%-67.1%$845.01MN/A-2.10100ELVNEnliven Therapeutics2.6447 of 5 stars$17.19+4.1%$40.33+134.6%-4.5%$842.38MN/A-9.0550Gap UpRCUSArcus Biosciences2.3869 of 5 stars$7.67-6.2%$30.25+294.4%-46.8%$806.41M$258M-2.43500Positive NewsCMRXChimerix2.7747 of 5 stars$8.54+0.2%$8.53-0.1%+844.7%$801.09M$212,000.00-9.0990Analyst ForecastNews CoverageCDMOAvid Bioservices0.8311 of 5 stars$12.50+0.1%$12.25-2.0%+86.2%$799.18M$139.91M-5.23320Upcoming EarningsHigh Trading VolumeSYRESpyre Therapeutics1.8238 of 5 stars$13.02+6.5%$49.57+280.7%-63.1%$784.55M$890,000.00-1.74100NTLAIntellia Therapeutics4.4067 of 5 stars$7.50+1.2%$37.56+400.7%-66.4%$776.38M$57.88M-1.38600ZYMEZymeworks2.7045 of 5 stars$11.00+3.5%$21.00+90.9%+30.3%$765.35M$76.30M-7.33460Positive News Related Companies and Tools Related Companies 89bio Alternatives Collegium Pharmaceutical Alternatives Dyne Therapeutics Alternatives Enliven Therapeutics Alternatives Arcus Biosciences Alternatives Chimerix Alternatives Avid Bioservices Alternatives Spyre Therapeutics Alternatives Intellia Therapeutics Alternatives Zymeworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMMP Stock Free IMMP Stock Alerts